DATE : 16-03-14 11:03
|
Gianturco-Roubin coronary stenting: Analysis of multicenter results.
|
|
|
WRITER :
stent
 HIT : 1,097
|
 C3._Korean_Circulation_J_1995;25_5_896-902..pdf (710.1K) [0] DATE : 2016-03-14 11:03:32 |
C3. Coronary stenting study groups; Gianturco-Roubin coronary stenting: Analysis of multicenter results. Korean Circulation J 1995;25(5)896-902.
(Abstract)
Initial Data
Seventy-three units of Gianturco-Roubin coronary stents were implanted in 70 patients, 49 male and 21 female, at 12 hospitals. The clinical characteristics of the patients were stable angina in 27(39%), unstable angina in 28(40%) and recent myocardial infarction in 15(21%) patients. The coronary angiographic findings were 32 single vessel(46%), 22 two vessel(31%) and 16 three vessel disease(23%). Angiographic morphological characteristics were type A in 13(18%), type B1in 16(22%), type B2in 31(42%) and type C in 13(18%) cases. Bail-out stenting for acute closure or threatened closure was performed in 43(59%) lesions and primary elective stenting was in 3(4%) lesions. IN the rest 27(37%) lesions, Gianturco-Roubin stent was deployed to potimize the angiographic result after balloon angioplasty. The coronary artery segments for the stenting were 35 left anterior descending arteries(47.9%), 10 left circumflex arteries(13.7%) and 28 right coronary arteries(38.4%). Gianturco-Roubin stents with diameter of larger than or equal to 3mm were were implanted in 61(84%) lesions.
The initial angiographic success rate was 93%(68/72) and clinical success rate was 96%(67/70). Complications during hospital stay was 1 Q-wave infarction, 2 emergent coronary bypass grafting, 1 repeat PTCA and 8(11%) cases of significant bleeding requiring transfusion.
Follow-up Data
Angiographic follow-up was done only in 17 patients(24.3%) at 6 months. Overall angiographic restenosis was found in 52%(9/17) of lesions using the definition of restenosis as narrowitng of luminal diameter of 50% or more.
Conclusion
Gianturco-Roubin coronary stention is a safe and effective therapeutic modality for optimization of PTCA results and for the bail-out procedure in acute closure or threatened closure after PTCA.
|
|
